ANIX
Anixa Biosciences, Inc. (ANIX) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
ANIX’s disclosed R&D intensity is minimal in the provided metrics, which limits evidence of peer-leading resource efficiency versus more disclosure-rich life-science peers.
The absence of reported gross margin and free-cash-flow margin data reduces comparability on operational environmental efficiency, leaving its relative positioning less transparent than peers.
Very low leverage can indirectly support environmental resilience by preserving flexibility for compliance and facility investments, but this is not a direct environmental differentiator versus peers.
No Tier 1 filing evidence was provided for emissions, energy use, or waste, so the environmental score reflects limited disclosed ESG differentiation rather than confirmed weakness.
Social
The provided metrics do not include workforce, safety, or product-access disclosures, which makes ANIX’s social positioning harder to verify against better-disclosed peers.
Minimal stock-based compensation relative to revenue suggests lower dilution pressure on employees and shareholders, but it is not a direct indicator of stronger labor practices versus peers.
As a small-cap healthcare company, ANIX likely faces elevated stakeholder scrutiny on product quality and patient impact, yet no disclosed controversy evidence was provided here.
Relative to peers with broader social reporting, ANIX appears neutral-to-lagging on transparency, which constrains confidence in a stronger social ESG profile.
Governance
ANIX’s very low debt-to-equity ratio indicates conservative balance-sheet governance, which reduces creditor pressure and supports oversight flexibility versus more levered peers.
Net debt to EBITDA is also low, suggesting limited financial risk-taking and a governance profile that is cleaner than many small-cap biotech peers.
The provided metrics show no stock-based compensation burden, which can support alignment and limit dilution concerns relative to peers with heavier equity compensation.
However, the absence of filing-based board, audit, and ownership disclosures prevents a stronger governance score, because peer-relative assessment depends on documented controls and independence.
Overall Score
ANIX screens as a moderate ESG performer relative to peers, with conservative leverage supporting governance, but limited disclosed environmental and social data constraining a stronger ranking.
Score Driver: Conservative Leverage And Low Financial Risk Support Governance, But Sparse ESG Disclosure Limits Peer-Relative Differentiation.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Anixa Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
